What FDA’s record states
| Field | What FDA’s record states | Source |
|---|---|---|
| Recipient | Cheap Medicine Shop/www.cheapmedicineshop.com | FDA letter ↗ |
| Location | Not published by FDA | n/a |
| Letter date | Sep 24, 2026 | FDA letter ↗ |
| Posted by FDA | Oct 6, 2026 | FDA index ↗ |
| Issuing office | Center for Drug Evaluation and Research (CDER) | FDA letter ↗ |
| Subject | Unapproved New Drugs/Misbranded (Internet Pharmacy) | FDA letter ↗ |
| MARCS-CMS number | 737810 | FDA letter ↗ |
| GLP-1 drugs named | Semaglutide | FDA letter ↗ |
| Response letter | Not published by FDA | FDA letter ↗ |
| Closeout letter | Not published by FDA | FDA letter ↗ |
“As discussed below, FDA has observed that www.cheapmedicineshop.com introduces into interstate commerce unapproved and misbranded injectable semaglutide drug products. There are inherent risks to consumers who purchase unapproved and misbranded drug products.”FDA warning letter to Cheap Medicine Shop/www.cheapmedicineshop.com, Sep 24, 2026 · read the full letter on fda.gov ↗
What this is and is not. A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.
Other GLP-1 letters FDA issued that week
Source
Every field above is copied from FDA’s page for this letter, read Oct 14, 2026. The letter on fda.gov ↗ · All 163 GLP-1 warning letters